Patent · US Active

T cell receptors and immune therapy using the same

US10590194B2 · kind B2 · utility

10Cited by

0References

17Claims

0Family size

Assignee

Immatics Biotechnologies GmbH · DE

Inventors

Claudia WAGNER · Lörrach, DE
Leonie ALTEN · Lörrach, DE
Sebastian BUNK · Wien, AT
Dominik MAURER · Lingen (Ems), DE

Key dates

Filing date	Jun 29, 2018
Grant date	Mar 17, 2020
Priority date	—
Expiry date	Jun 29, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2015/8518
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.